Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Clinical trial design is a key aspect of the successful conduct of clinical trials. It involves deciding parameters such as the number of patients, the length of the trial, the comparator arm (in the case of randomized controlled trials) using information on current treatments, the anticipated effect of the therapeutic intervention being studied and applying biostatistics methods.
Post hoc analysis of the DAPA-HF and DELIVER trials reports on the approach of win statistics to evaluate the effect of dapagliflozin on a hierarchical composite kidney outcome in patients with heart failure.
In an open-label phase 2 trial, patients with non-small-cell lung cancer received neoadjuvant anti-PD-1 with or without anti-LAG-3, showing that curative intent surgery after combined blockade of PD-1 and LAG-3 is feasible, and leads to preliminary clinical responses.
The lay summary of trial results to be provided to participants should be written in plain language, use infographics and be concise — something that currently is almost never achieved.
A randomized controlled trial involving a telemedicine-based approach for the management of patients with acute coronary syndrome had several clinical benefits relative to standard of care.
An argument framework, grounded in the sciences of reasoning, provides an alternative to medicine’s measurement framework for evaluating and synthesizing evidence in healthcare.
An mRNA-based drug aims to replace a faulty enzyme and restore metabolic function in children with propionic acidemia — with encouraging early clinical results.